Index Entries

A. P. Arévalo, R. Pagotto, J. L. Pórfido, H. Daghero, M. Segovia, K. Yamasaki, B. Varela, M. Hill, J. M. Verdes, M. Duhalde Vega, M. Bollati-Fogolín, and M. Crispo
March 30, 2021
Scientific Reports
Institut Pasteur de Montevideo (Uruguay)

Abstract: The objective of this study was to test the effectiveness of ivermectin for the treatment of mouse hepatitis virus (MHV), a type 2 family RNA coronavirus similar to SARS-CoV-2… Overall, the results demonstrated that viral infection induced typical MHV-caused disease, with the livers showing severe hepatocellular necrosis surrounded by a severe lymphoplasmacytic inflammatory infiltration associated with a high hepatic viral load (52,158 AU), while mice treated with ivermectin showed a better health status with a lower viral load (23,192 AU; p <?0.05), with only a few having histopathological liver damage (p < 0.05)… In conclusion, ivermectin diminished the MHV viral load and disease in the mice, being a useful model for further understanding this therapy against coronavirus diseases.”

document
COVID-19,ivermectin,medical treatments,pharmaceuticals